Q1 2026 Altimmune Inc Earnings Call Transcript
Key Points
- Altimmune Inc (ALT) completed an oversubscribed public offering, raising USD225 million, resulting in a strong cash position of USD535 million.
- The company is fully funded through the Phase III MASH 52-week data readout expected in 2029, highlighting financial stability.
- Pemvidutide has received breakthrough therapy designation in MASH by the FDA, indicating its potential significance in treating hepatic diseases.
- The Phase II IMPACT trial showed strong efficacy results, particularly at the 1.8 mg dose, with plans to introduce a 2.4 mg dose in Phase III for potentially increased efficacy.
- Altimmune Inc (ALT) has aligned its Phase III trial design with both FDA and EMA feedback, ensuring regulatory compliance and strategic advancement.
- R&D expenses increased to USD16.2 million in Q1 2026, driven by ongoing trials and start-up costs for the Phase III MASH trial.
- G&A expenses rose to USD8.1 million, primarily due to increased severance costs and professional fees.
- The net loss for Q1 2026 was USD22.6 million, compared to USD19.6 million in the same period of 2025, indicating financial challenges.
- The company faces competition from other GLP-1 based therapies, which have been associated with GI side effects leading to discontinuations.
- There is uncertainty regarding the final endpoints for the Phase III AUD trial, as discussions with the FDA are ongoing.
Good morning, ladies and gentlemen, and welcome to the Altimmune first quarter 2026 financial results conference call. (Operator Instructions) As a reminder, this call is being recorded. I'll now introduce your host for today's conference call, Luis Sanay, Vice President of Investor Relations. Luis, you may begin.
Thank you, operator. Good morning, everyone. Thank you for joining us for Altimmune's first quarter 2026 financial results and business update call. On today's call, you will hear from Jerry Durso, our President and Chief Executive Officer; Dr. Christophe Arbet-Engels, Chief Medical Officer; Linda Richardson, Chief Commercial Officer; and Greg Weaver, Chief Financial Officer. Following management's prepared remarks, we'll open the line for the Q&A session. Our first quarter 2026 earnings release was issued this morning and can be found on the Investor Relations section of our website.
Before we begin, I would like to remind everyone that remarks made about future
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
